Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 June;57(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 June;57(2):134-45

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REVIEWS  MIBG IN THE DIAGNOSIS AND THERAPY OF PHEOCHROMOCYTHOMA AND PARAGANGLIOMAFREEfree


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 June;57(2):134-45

Copyright © 2013 EDIZIONI MINERVA MEDICA

lingua: Inglese

Gallium-68 DOTANOC imaging in paraganglioma/pheochromocytoma: presentation of sample cases and review of the literature

Lopci E. 1, Zanoni L. 2, Fanti S. 2, Ambrosini V. 2, Castellani M. R. 3, Aktolun C. 4, Chiti A. 1

1 Nuclear Medicine Department Humanitas Clinical and Research Center Rozzano (MI), Italy; 2 PET Unit, Nuclear Medicine Department Ospedale Universitario S.Orsola, Bologna, Italy; 3 Nuclear Medicine Division National Cancer Institute, Milan, Italy; 4 Molecular Imaging Program at Stanford Department of Radiology Stanford University School of Medicine, Stanford, USA


FULL TEXT  


Gallium-68 DOTANOC is a high affinity somatostatin receptor ligand, first introduced in 2005 for imaging neuroendocrine tumors. Due to its technically simple production, broad availability, favourable biodistribution and advantageous dosimetry, although not approved yet in all European countries, gallium-68 DOTANOC has rapidly gained acceptance in the diagnostic and therapeutic work-flow of different types of neuroendocrine tumors. Principal indications in clinical practice in countries where it is officially approved include diagnosis and staging, restaging after treatment, identification of sites of unknown primary and selection of patients with neuroendocrine tumors eligible for therapy with somatostatin analogues.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

egesta.lopci@gmail.com